34 results
Page of 3
  • ACCL1333

    A study designed to evaluate the safety and efficacy of Apixaban for Thromboembolism Prevention versus No Systemic Anticoagulant Prophylaxis during Induction Chemotherapy in children with newly diagnosed Acute Lympho.

    Type: Treatment

    Principal Investigator: Richard Drachtman, MD

    Trial is open for enrollment

    For inquiries, call (732) 235-8861
    • Rutgers Robert Wood Johnson Medical School
    • Robert Wood Johnson University Hospital
  • ACURATE

    Evaluation of the safety and efficacy of the Acurate valve for transcatheter aortic valve replacement (TAVR)

    Type: Device trial

    Principal Investigator: Mark Russo, MD

    Trial is open for enrollment

    For inquiries, call (732) 235-9215

    • Rutgers Robert Wood Johnson Medical School
    • Robert Wood Johnson University Hospital
  • AEGIS II

    A phase 3, multi-center, double-blind, randomized, placebo-controlled, parallel-group study designed to investigate the efficacy and safety of CSL 112 (Apolipoprotein A-I: human) on reducing the risk of major adverse CV events in subjects with acute coronary syndrome (ACS) diagnosed with either ST-segment elevation myocardial infarction (STEMI) or non-ST-segment elevation myocardial infarction (NSTEMI), including those managed with percutaneous coronary intervention (PCI) or medically managed.

    Type: Treatment

    Trial is open for enrollment

    View All Details

    • Principal Investigator:
      Sharan Mahal, MD

    For inquiries, call (908) 864-4027
    • Robert Wood Johnson University Hospital
  • ALIGN-AR

    This study will examine the use of TAVR (Transcatheter Aortic Valve Replacement), which is a minimally invasive procedure designed to replace the aortic valve inside the heart. In this study, TAVR will be performed using the JenaValve Pericardial TAVR System, which is intended to help treat severe aortic regurgitation.

    Type: Device trial

    Principal Investigator: Mark Russo, MD

    Trial is open for enrollment

    For inquiries, call (732) 235-9215

    • Rutgers Robert Wood Johnson Medical School
    • Robert Wood Johnson University Hospital
  • ALIGN-AS

    This study will examine the use of a TAVR (Transcatheter Aortic Valve Replacement), which is a minimally invasive procedure designed to replace the aortic valve inside the heart. This less invasive surgical approach called TAVR is offered to those patients who are high risk for undergoing open heart surgery to replace the aortic valve. In this study, TAVR will be performed using the JenaValve Pericardial TAVR System.

    Type: Device trial

    Principal Investigator: Mark Russo, MD

    Trial is open for enrollment

    For inquiries, call (732) 235-9215

    • Rutgers Robert Wood Johnson Medical School
    • Robert Wood Johnson University Hospital
  • AMULET

    A study designed to evaluate the safety and effectiveness of the AMPLATZER Amulet Left Atrial Appendage Occluder.

    Type: Device trial

    Trial is not open for enrollment

    For inquiries, call (973) 926-6938
    • Saint Barnabas Medical Center
  • ARRAY 797-301

    A phase 3, multinational, randomized, placebo-controlled study of ARRY-371797 in patients with symptomatic dilated cardiomyopathy due to a lamin A/C gene mutation.

    Type: Drug trial

    Principal Investigator: Saurabh Kapoor, MD

    Trial is open for enrollment

    For inquiries, call (973) 926-8451
    • Newark Beth Israel Medical Center
  • ASAP-TOO

    The purpose of this study is to establish the safety and effectiveness of the WATCHMAN™ Left Atrial Appendage Closure (LAAC) Device, including the post-implant medication regimen, for subjects with non-valvular atrial fibrillation who are deemed not to be eligible for anti-coagulation therapy to reduce the risk of stroke.

    Type: Device trial

    Principal Investigator: David Dobesh, MD

    Trial is open for enrollment

    For inquiries, call (973) 736-6333
    • Saint Barnabas Medical Center
  • CIRT

    A randomized clinical trial investigating whether taking low-dose methotrexate reduces heart attacks, strokes, or death in people with type 2 diabetes or metabolic syndrome that have had a heart attack or multiple coronary blockages.

    Type: Drug trial

    Principal Investigator: John B. Kostis, MD

    Trial is open for enrollment

    For inquiries, call (732) 235-6546
    • Rutgers Robert Wood Johnson Medical School
    • Robert Wood Johnson University Hospital
  • CLASP IID & IIF

    Evaluation of the safety and effectiveness of transcatheter mitral valve repair with the Edwards PASCAL Transcatheter Valve Repair System compared to Abbott MitraClip in patients with degenerative mitral regurgitation (DMR) who have been determined to be at prohibitive risk for mitral valve surgery by the Heart Team, and in patients with functional mitral regurgitation (FMR) on guideline directed medical therapy (GDMT)

    Type: Device trial

    Principal Investigator: Mark Russo, MD

    Trial is open for enrollment

    For inquiries, call (732) 235-9215

    • Rutgers Robert Wood Johnson Medical School
    • Robert Wood Johnson University Hospital
  • COMPASSION XT PAS

    Evaluation of the longer-term safety and effectiveness of the SAPIEN XT transcatheter heart valve (THV) in the pulmonic position for the intended patient population (especially pediatric) when used as indicated with all valve sizes.

    Type: Device trial

    Principal Investigator: Marc Cohen, MD and Rajiv Verma, MD

    Trial is open for enrollment

    For inquiries, call (973) 926-8451
    • Newark Beth Israel Medical Center
  • Connect-HF

    A large-scale, pragmatic, cluster-randomized clinical trial to evaluate the effect of a customized, multi-faceted, health system-level quality improvement (QI) program compared with usual care on heart failure (HF) outcomes and HF quality-of-care metrics

    Type: Treatment

    Trial is open for enrollment

    View All Details

    • Principal Investigator:
      Sharan Mahal, MD

    For inquiries, call (908) 864-4027
    • Robert Wood Johnson University Hospital
Page of 3